Androgen Receptor Expression in Thai Breast Cancer Patients
AbstractThe aim of this study was to investigate prevalence and related factors of androgen receptor (AR) expression in Thai breast cancer patients. A descriptive study was done in 95 patients, who were admitted to Charoenkrung Pracharak Hospital, Bangkok (2011–2013). Statistical relationships were examined between AR protein expression, tumor status, and patient characteristics. Compared with those from Western countries, ethnic Thai patients were younger at age of diagnosis and had a higher proliferative index (high Ki-67 expression), which indicates unfavorable prognosis. In addition, 91% of the Thai breast tumors that were positive for any of the following receptors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) also expressed the AR protein, while in triple negative breast tumors only 33% were AR positive. ER and PR expression was positively related with AR expression, while AR expression was inversely correlated to Ki-67 expression. AR status was strongly correlated with ER and PR status in Thai patients. There is an inverse relationship between Ki-67 and AR, which suggests that AR may be a prognostic factor for breast cancer. View Full-Text
Share & Cite This Article
Chottanapund, S.; Van Duursen, M.B.M.; Ratchaworapong, K.; Navasumrit, P.; Ruchirawat, M.; Van den Berg, M. Androgen Receptor Expression in Thai Breast Cancer Patients. Med. Sci. 2016, 4, 15.
Chottanapund S, Van Duursen MBM, Ratchaworapong K, Navasumrit P, Ruchirawat M, Van den Berg M. Androgen Receptor Expression in Thai Breast Cancer Patients. Medical Sciences. 2016; 4(3):15.Chicago/Turabian Style
Chottanapund, Suthat; Van Duursen, M. B.M.; Ratchaworapong, Kumpol; Navasumrit, Panida; Ruchirawat, Mathuros; Van den Berg, Martin. 2016. "Androgen Receptor Expression in Thai Breast Cancer Patients." Med. Sci. 4, no. 3: 15.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.